论文部分内容阅读
目的:探讨血浆脑钠肽(BNP)水平对高原心脏病的诊断价值及预后评估。方法:89例高原心脏病患者按美国纽约心脏病学会心功能分级(NYHA),采用免疫荧光法对患者治疗前后进行血浆脑钠肽检测,并与正常健康人70例(对照组)的血浆脑钠肽的水平进行比较。结果:血浆脑钠肽水平随着NYHA分级增高而升高,差异有统计学意义(P<0.01)。结论:血浆脑钠肽水平可作为临床诊断HAHD的指标并可评估患者预后。
Objective: To investigate the diagnostic value and prognosis of plasma brain natriuretic peptide (BNP) in patients with altitude heart disease. Methods: Eighty-nine patients with plateau heart disease were enrolled in this study. According to the New York Heart Association Society of Cardiology (NYHA), plasma brain natriuretic peptide was detected by immunofluorescence before and after treatment. The plasma brain natriuretic peptide The level of natriuretic peptide is compared. Results: The level of plasma brain natriuretic peptide increased with the increase of NYHA classification, the difference was statistically significant (P <0.01). Conclusion: The level of plasma brain natriuretic peptide can be used as an index for clinical diagnosis of HAHD and the prognosis of patients can be evaluated.